Vaccine composition

• US 10,363,293 B2
• Filed: 02/20/2014
• Issued: 07/30/2019
• Est. Priority Date: 02/21/2013
• Status: Active Grant

• Current Assignee: Turnstone Limited Partnership
• Original Assignee: Turnstone Limited Partnership
• Inventors: Stojdl, David F., Bell, John Cameron, Lichty, Brian, Pol, Jonathan
• Primary Examiner(s): Foley, Shanon A.
• Assistant Examiner(s): Hill, Myron G
• Application Number:
  US14/769,035
• Publication Number:
  US 20160106820A1
• Time in Patent Office: 1,986 Days
• Field of Search: None
• CPC Class Codes: A61K 2039/5254 avirulent or attenuated
• CPC Class Codes: A61K 2039/5256 expressing foreign proteins
• CPC Class Codes: A61K 2039/545 characterised by the dose, timing or administration schedule
• CPC Class Codes: A61K 2039/55561 CpG containing adjuvants; Oligonucleotide containing adjuvants
• CPC Class Codes: A61K 2039/572 cytotoxic response
• CPC Class Codes: A61K 2039/585 wherein the target is cancer
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 35/766 Rhabdovirus, e.g. vesicular stomatitis virus
• CPC Class Codes: A61K 39/0005 Vertebrate antigens from snakes A61K39/38
• CPC Class Codes: A61K 39/0011 Cancer antigens
• CPC Class Codes: A61K 39/001184 Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
• CPC Class Codes: A61K 39/001186 MAGE
• CPC Class Codes: A61K 39/12 Viral antigens
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: C07K 2319/50 containing protease site
• CPC Class Codes: C12N 15/86 Viral vectors
• CPC Class Codes: C12N 2710/10343 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2710/16234 : Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 2710/20034 : Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 2740/15043 : viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2760/20223 : Virus like particles [VLP]
• CPC Class Codes: C12N 2760/20232 : Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
• CPC Class Codes: C12N 2760/20242 : virus or viral particle as vehicle, e.g. encapsulating small organic molecule
• CPC Class Codes: C12N 2760/20243 : viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 7/00 : Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00

Abstract

There is described a kit for use in inducing an immune response in a mammal, the kit includes: a first virus that expresses MAGEA3, Human Papilloma Virus E6/E7 fusion protein, human Six-Transmembrane Epithelial Antigen of the Prostate protein, or Cancer Testis Antigen 1, or a variant thereof as an antigenic protein and that is formulated to generate an immunity to the protein or variant thereof in the mammal. The kit also includes a Maraba MG1 virus encoding the same antigen, or a variant of the same antigen. The Maraba MG1 virus is formulated to induce the immune response in the mammal. The first virus is immunologically distinct from the Maraba MG1 virus.

Claims

1. A method for treating a patient having a cancer, said method comprising:

a) a first virus, said first virus comprising a nucleic acid that is capable of expressing a MAGEA3 protein, said MAGEA3 protein comprising an amino acid sequence that is at least 70% identical to SEQ ID NO;

1, and includes at least one MAGEA3 tumor-associated epitope selected from the group consisting of;

FLWGPRALV (SEQ ID NO;

     27), KVAELVHFL (SEQ ID NO;

     28), EGDCAPEEK (SEQ ID NO;

     35), KKLLTQHFVQENYLEY (SEQ ID NO;

     36), and RKVAELVHFLLLKYR (SEQ ID NO;

     37), wherein said MAGEA3 protein is capable of inducing an immune response in a patient in a heterologous prime-boost format, and

b) a second virus, said second virus being a Maraba MG1 virus comprising a nucleic acid that is capable of expressing a MAGEA3 protein, said MAGEA3 protein comprising an amino acid sequence that is at least 70% identical to SEQ ID NO;

1, and includes at least one MAGEA3 tumor-associated epitope selected from the group consisting of;

FLWGPRALV (SEQ ID NO;

     27), KVAELVHFL (SEQ ID NO;

     28), EGDCAPEEK (SEQ ID NO;

     35), KKLLTQHFVQENYLEY (SEQ ID NO;

     36), and RKVAELVHFLLLKYR (SEQ ID NO;

     37), wherein said Maraba MG1 virus is formulated for use in providing a therapeutic oncolytic effect in said patient;

wherein;

said first virus is immunologically distinct from said second virus;

said first virus is a priming virus and administered before said second virus; and

wherein

said second virus is a boost virus and is administered at least twice after administration of said priming virus.

2. The method of claim 1, wherein

a) said first virus is a negative strand RNA virus and includes a reverse complement and RNA version of a transgene comprising a nucleotide sequence of SEQ ID NO:

2;

b) said first virus is a DNA virus or a positive sense RNA virus and includes a transgene comprising a nucleotide sequence of SEQ ID NO;

2;

c) said second virus includes a reverse complement and RNA version of a transgene comprising a nucleotide sequence of SEQ ID NO;

2;

or

d) (i) said first virus is a negative strand RNA virus and includes a reverse complement and RNA version of a transgene comprising a nucleotide sequence of SEQ ID NO;

2 and said second virus includes a reverse complement and RNA version of a transgene comprising a nucleotide sequence of SEQ ID NO;

2;

or

(ii) said first virus is a DNA virus or a positive sense RNA virus and includes a transgene comprising a nucleotide sequence of SEQ ID NO;

2 and said second virus includes a reverse complement and RNA version of a transgene comprising a nucleotide sequence of SEQ ID NO;

2.

3. The method of claim 1, wherein

a) said first virus is a negative strand RNA virus and includes a reverse complement and RNA version of a codon optimized transgene comprising a nucleotide sequence of SEQ ID NO:

3;

or

b) said first virus is a DNA virus or a positive sense RNA virus and includes a codon optimized transgene comprising a nucleotide sequence of SEQ ID NO;

3;

or

c) said second virus includes a reverse complement and RNA version of a codon optimized transgene comprising a nucleotide sequence of SEQ ID NO;

3;

or

d) (i) said first virus is a negative strand RNA virus and includes a reverse complement and RNA version of a codon optimized transgene comprising a nucleotide sequence of SEQ ID NO;

3 and said second virus includes a reverse complement and RNA version of a codon optimized transgene comprising a nucleotide sequence of SEQ ID NO;

3, or

(ii) said first virus is a DNA virus or a positive sense RNA virus and includes a codon optimized transgene comprising a nucleotide sequence of SEQ ID NO;

3 and said second virus includes a reverse complement and RNA version of a codon optimized transgene comprising a nucleotide sequence of SEQ ID NO;

3.

4. The method of claim 1, wherein at least one of said MAGEA3 proteins comprises an amino acid sequence that is at least 80% identical to SEQ ID NO:

1.

5. The method of claim 4, wherein at least one of said MAGEA3 proteins comprises an amino acid sequence that is at least 90% identical to SEQ ID NO:

1.

6. The method of claim 5, wherein at least one of said MAGEA3 proteins comprises an amino acid sequence that is at least 95% identical to SEQ ID NO:

1.

7. The method of claim 6, wherein at least one of said MAGEA3 proteins comprises an amino acid sequence that is SEQ ID NO:

1.

8. The method of claim 1, wherein at least one of said MAGEA3 proteins comprises an amino acid sequence that is SEQ ID NO:

4.

9. The method of claim 1, wherein at least one of said MAGEA3 proteins comprises an amino acid sequence that is encoded by the nucleotide sequence of SEQ ID NO:

5.

10. The method of claim 1, wherein

a) said first virus is a negative sense RNA virus and includes a reverse complement and RNA version of a nucleotide sequence encoding the MAGEA3 protein of SEQ ID NO:

4 and said second virus includes a reverse complement and RNA version of a nucleotide sequence encoding the MAGEA3 protein of SEQ ID NO;

1;

b) said first virus is a negative sense RNA virus and includes a reverse complement and RNA version of a nucleotide sequence encoding the MAGEA3 protein of SEQ ID NO;

1 and said second virus includes a reverse complement and RNA version of a nucleotide sequence encoding the MAGEA3 protein of SEQ ID NO;

4;

c) said first virus is a DNA or RNA virus and includes a nucleotide sequence encoding the MAGEA3 protein of SEQ ID NO;

4 and said second virus includes a reverse complement and RNA version of a nucleotide sequence encoding the MAGEA3 protein of SEQ ID NO;

1;

or

d) said first virus is a DNA or RNA virus and includes a nucleotide sequence encoding the MAGEA3 protein of SEQ ID NO;

1 and said second virus includes a reverse complement and RNA version of a nucleotide sequence encoding the MAGEA3 protein of SEQ ID NO;

4.

11. The method of claim 1, wherein the sequence of said MAGEA3 protein that is expressed by said first virus and the sequence of said MAGEA3 protein that is expressed by said second virus, are identical.

12. The method of claim 1, wherein at least one of said first virus and said second virus comprises a nucleic acid that is capable of expressing the MAGEA3 protein of SEQ ID NO:

1, and at least one of said first virus and said second virus comprises a nucleic acid that is capable of expressing the MAGEA3 protein of SEQ ID NO;

4.

13. The method of claim 1, wherein said first virus is an adenovirus.

14. The method of claim 1, wherein said second virus is first administered about 24 hours after the administration of said first virus.

15. The method of claim 1, wherein said second virus is first administered about 2-4 days after the administration of said first virus.

16. The method of claim 1, wherein said second virus is first administered about 1 week after the administration of said first virus.

17. The method of claim 1, wherein said second virus is first administered about 2 weeks after the administration of said first virus.

18. The method of claim 1, wherein said second virus is administered about 3 days after the first administration of said second virus.

19. The method of claim 1, wherein said first virus is administered intramuscularly.

20. The method of claim 1, wherein said second virus is administered intravenously.

21. The method of claim 1, wherein:

a) said first virus is an adenovirus; and

b) said first virus comprises a nucleic acid that is capable of expressing the MAGEA3 protein of SEQ ID NO;

1, and said second virus comprises a nucleic acid that is capable of expressing the MAGEA3 protein of SEQ ID NO;

1;

wherein;

said second virus is administered intravenously first about 2 weeks after an intramuscular administration of said first virus; and

wherein

said second virus is administered intravenously about 3 days after said first intravenous administration of said second virus.